Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncobix Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, RODRIGUEZ-GARCIA, VALERIE, who is also identified as the busiest examiner for the portfolio with 1 pending action. The concentration of work is further reflected in the involvement of only 1 distinct art unit for the entire pending portfolio.
The presence of 1 distinct examiner across 1 distinct art unit suggests a focused prosecution effort. With RODRIGUEZ-GARCIA, VALERIE managing the only pending office action, the company's current interactions with the patent office are centralized. This alignment between the technology area and the specific art unit indicates that the portfolio's current legal challenges are confined to a narrow technical and administrative scope. Practitioners can observe that the workload is not distributed across multiple individuals, as the 1 pending action represents the entirety of the active examiner engagement for this entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715996 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | RODRIGUEZ-GARCIA, VALERIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715996 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | RODRIGUEZ-GARCIA, VALERIE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715996 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103§112 | Non-Final OA | — | Pending | Jun 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncobix Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Valerie Rodriguez-Garcia has the most, with 1 of Oncobix Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
